Genital Herpes Simplex Type 2
7
0
1
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (7)
A Clinical Trial in Healthy Volunteers and Volunteers With Recurrent Genital Herpes to Study the Safety, Tolerability, and Immune Responses After Vaccination With an Investigational Vaccine Designed to Prevent Genital Herpes Lesions
Safety and Efficacy Trial of DNA Vaccines to Treat Genital Herpes in Adults
Safety and Immunogenicity Study of Therapeutic HSV-2 Vaccine
Evaluating New Formulation of Therapeutic HSV-2 Vaccine
Long-term Follow-up of GEN-003-002 Subjects for Efficacy and Immunogenicity
Dose Ranging Safety and Efficacy of Therapeutic HSV-2 Vaccine
Rollover Trial for Placebo Subjects Previously Enrolled Into GEN-003-002 Study